·论著·577中国临床医生杂志2023年第51卷第5期200～500µg/L的MHD患者的肾性贫血的效果优于RhuEPO联合静脉铁剂，且罗沙司他治疗肾性贫血无铁过载风险、安全性更高。与RhuEPO联合静脉铁剂的治疗方案相比，罗沙司他在SF为200～500µg/L的MHD患者的肾性贫血的治疗中具有临床应用价值。参考文献：[1]中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识(2018修订版)[J].中华肾脏病杂志,2018,34(11):860-866.[2]中国医师协会肾脏内科医师分会肾性贫血指南工作组.中国肾性贫血诊治临床实践指南[J].中华医学杂志,2021,101(20):1463-1502.[3]BABITTJL,LINHY.MechanismsofanemiainCKD[J].JAmSocNephrol,2012,23(10):1631-1634.[4]HAYASHIT,JOKIN,TANAKAY,etal.Anaemiaandearlyphasecardiovasculareventsonhaemodialysis.[J].Nephrology(Carlton),2015,20Suppl4(s4):1-6.[5]KLIGERAS,FOLEYRN,GOLDFARBDS,etal.KDOQIUSCommentaryonthe2012KDIGOClinicalPracticeGuidelineforAnemiainCKD[J].AmJKidneyDis,2013,62(5):849-859.[6]MACGINLEYR,WALKERR,IRVINGM.KHA-CARIGuideline:useofironinchronickidneydiseasepatients.[J].Nephrology(Carlton),2013,18(12):747-749.[7]ROSTOKERG,GRIUNCELLIM,LORIDONC,etal.Hemodialysis-associatedhemosiderosisintheeraoferythropoiesis-stimulatingagents:AMRIstudy[J].AmJMed,2012,125(10):991-999,e1.[8]陈晓农,高琛妮.肾性贫血的诊治进展[J].内科理论与实践,2021,16(01):10-14.[9]李川,龚德华.慢性肾脏病患者贫血治疗中铁剂的应用[J].肾脏病与透析肾移植杂志,2016,25(3):279-285.[10]DELVECCHIOL,LOCATELLIF.Clinicalpracticeguidelinesonirontherapy:Acriticalevaluation.[J].HemodialInt,2017,21(Suppl1):S125-S131.[11]PROVENZANOR,BESARABA,WRIGHTS,etal.Roxadustat(FG-4592)versusepoetinalfaforanemiainpatientsreceivingmaintenancehemodialysis:aphase2,randomized,6-to19-week,open-label,active-comparator,dose-ranging,safetyandexploratoryefficacystudy[J].AmJKidneyDis,2016,67(6):912-924.[12]孙凌霜,薛瑾虹,魏萌,等.罗沙司他替代大剂量重组人红细胞生成素治疗维持性血液透析患者贫血的疗效[J].肾脏病与透析肾移植杂志,2021,30(3):217-221.[13]刘章锁,王沛.K/DOQI指南关于慢性肾脏病分期的临床指导意义[J].中国实用内科杂志,2008,28(1):21-24.[14]洪大情,田恩,李明珠...
